Comparative Pharmacology
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus LOTUSATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus LOTUSATE.
ELASE-CHLOROMYCETIN vs LOTUSATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
LOTUSATE is a selective serotonin reuptake inhibitor (SSRI) that inhibits the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin activity in the central nervous system and thereby exerting antidepressant and anxiolytic effects.
Topical application: Apply thin layer to affected area 2-3 times daily.
100 mg orally twice daily, with or without food.
None Documented
None Documented
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Terminal elimination half-life is 3.5-4.5 hours in healthy adults; prolonged to 8-10 hours in moderate hepatic impairment, requiring dose adjustment.
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Primarily renal excretion of unchanged drug (65-75%) with 15-20% as glucuronide conjugate; 10-15% eliminated via feces.
Category C
Category C
Topical Antibiotic and Debriding Agent
Topical Antibiotic